TransMedics Group (NASDAQ:TMDX – Get Free Report) and Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Earnings and Valuation
This table compares TransMedics Group and Bluejay Diagnostics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransMedics Group | $605.49 million | 4.16 | $190.29 million | $4.40 | 16.57 |
| Bluejay Diagnostics | N/A | N/A | -$6.85 million | ($11.63) | -0.42 |
Analyst Ratings
This is a breakdown of current recommendations and price targets for TransMedics Group and Bluejay Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TransMedics Group | 0 | 7 | 6 | 0 | 2.46 |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
TransMedics Group presently has a consensus target price of $134.00, indicating a potential upside of 83.79%. Given TransMedics Group’s stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bluejay Diagnostics.
Profitability
This table compares TransMedics Group and Bluejay Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransMedics Group | 27.04% | 22.38% | 8.46% |
| Bluejay Diagnostics | N/A | -144.27% | -115.00% |
Insider & Institutional Ownership
99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
TransMedics Group has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Summary
TransMedics Group beats Bluejay Diagnostics on 13 of the 13 factors compared between the two stocks.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
